Determination of engraftment potential of human cord blood stem-progenitor cells as a function of donor cell dosage and gestational age in the NOD/SCID mouse model

Serdar H. Ural, Mary D. Sammel, Karin Blakemore

Research output: Contribution to journalArticle

Abstract

Objective: The purpose of this study was to determine cell dosage parameters for successful engraftment of human cord blood hematopoietic stem cells (HSC) using an in vivo assay system, and to determine if there are differences with donor gestational age. Study design: HSCs were transplanted into nonobese diabetic-severe combined immunodeficient (NOD/SCID) mice. Donor cell dosage and gestational age ranges were 1 to 40×106 CD34+ cells per mouse, and 23 to 40 weeks, respectively. Recipient bone marrow was assessed for engraftment capacity of the HSCs. Results: There was increasing engraftment levels with increasing dosages of transplanted HSCs. When controlled for donor HSC dosage, engraftment levels using donor cord blood from earlier gestational ages were not different from that seen using later gestational ages. Conclusion: Similar dose responses are seen using HSCs derived from the late second trimester until term in engraftment potential in the NOD/SCID mouse model. Results from this study may be applicable to human postnatal and in utero transplantation studies.

Original languageEnglish (US)
Pages (from-to)990-994
Number of pages5
JournalAmerican Journal of Obstetrics and Gynecology
Volume193
Issue number3 SUPPL.
DOIs
StatePublished - Sep 2005

Fingerprint

SCID Mice
Fetal Blood
Gestational Age
Blood Cells
Stem Cells
Hematopoietic Stem Cells
Second Pregnancy Trimester
Transplantation
Bone Marrow

Keywords

  • Gestational age
  • Human stem cell
  • NOD/SCID mouse

ASJC Scopus subject areas

  • Medicine(all)
  • Obstetrics and Gynecology

Cite this

@article{10ec56383f7747529d658c001d6f44ec,
title = "Determination of engraftment potential of human cord blood stem-progenitor cells as a function of donor cell dosage and gestational age in the NOD/SCID mouse model",
abstract = "Objective: The purpose of this study was to determine cell dosage parameters for successful engraftment of human cord blood hematopoietic stem cells (HSC) using an in vivo assay system, and to determine if there are differences with donor gestational age. Study design: HSCs were transplanted into nonobese diabetic-severe combined immunodeficient (NOD/SCID) mice. Donor cell dosage and gestational age ranges were 1 to 40×106 CD34+ cells per mouse, and 23 to 40 weeks, respectively. Recipient bone marrow was assessed for engraftment capacity of the HSCs. Results: There was increasing engraftment levels with increasing dosages of transplanted HSCs. When controlled for donor HSC dosage, engraftment levels using donor cord blood from earlier gestational ages were not different from that seen using later gestational ages. Conclusion: Similar dose responses are seen using HSCs derived from the late second trimester until term in engraftment potential in the NOD/SCID mouse model. Results from this study may be applicable to human postnatal and in utero transplantation studies.",
keywords = "Gestational age, Human stem cell, NOD/SCID mouse",
author = "Ural, {Serdar H.} and Sammel, {Mary D.} and Karin Blakemore",
year = "2005",
month = "9",
doi = "10.1016/j.ajog.2005.05.051",
language = "English (US)",
volume = "193",
pages = "990--994",
journal = "American Journal of Obstetrics and Gynecology",
issn = "0002-9378",
publisher = "Mosby Inc.",
number = "3 SUPPL.",

}

TY - JOUR

T1 - Determination of engraftment potential of human cord blood stem-progenitor cells as a function of donor cell dosage and gestational age in the NOD/SCID mouse model

AU - Ural, Serdar H.

AU - Sammel, Mary D.

AU - Blakemore, Karin

PY - 2005/9

Y1 - 2005/9

N2 - Objective: The purpose of this study was to determine cell dosage parameters for successful engraftment of human cord blood hematopoietic stem cells (HSC) using an in vivo assay system, and to determine if there are differences with donor gestational age. Study design: HSCs were transplanted into nonobese diabetic-severe combined immunodeficient (NOD/SCID) mice. Donor cell dosage and gestational age ranges were 1 to 40×106 CD34+ cells per mouse, and 23 to 40 weeks, respectively. Recipient bone marrow was assessed for engraftment capacity of the HSCs. Results: There was increasing engraftment levels with increasing dosages of transplanted HSCs. When controlled for donor HSC dosage, engraftment levels using donor cord blood from earlier gestational ages were not different from that seen using later gestational ages. Conclusion: Similar dose responses are seen using HSCs derived from the late second trimester until term in engraftment potential in the NOD/SCID mouse model. Results from this study may be applicable to human postnatal and in utero transplantation studies.

AB - Objective: The purpose of this study was to determine cell dosage parameters for successful engraftment of human cord blood hematopoietic stem cells (HSC) using an in vivo assay system, and to determine if there are differences with donor gestational age. Study design: HSCs were transplanted into nonobese diabetic-severe combined immunodeficient (NOD/SCID) mice. Donor cell dosage and gestational age ranges were 1 to 40×106 CD34+ cells per mouse, and 23 to 40 weeks, respectively. Recipient bone marrow was assessed for engraftment capacity of the HSCs. Results: There was increasing engraftment levels with increasing dosages of transplanted HSCs. When controlled for donor HSC dosage, engraftment levels using donor cord blood from earlier gestational ages were not different from that seen using later gestational ages. Conclusion: Similar dose responses are seen using HSCs derived from the late second trimester until term in engraftment potential in the NOD/SCID mouse model. Results from this study may be applicable to human postnatal and in utero transplantation studies.

KW - Gestational age

KW - Human stem cell

KW - NOD/SCID mouse

UR - http://www.scopus.com/inward/record.url?scp=24644484786&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24644484786&partnerID=8YFLogxK

U2 - 10.1016/j.ajog.2005.05.051

DO - 10.1016/j.ajog.2005.05.051

M3 - Article

C2 - 16157099

AN - SCOPUS:24644484786

VL - 193

SP - 990

EP - 994

JO - American Journal of Obstetrics and Gynecology

JF - American Journal of Obstetrics and Gynecology

SN - 0002-9378

IS - 3 SUPPL.

ER -